

COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

RESEARCH REPORT



Genetic Testing.

Global Market Forecasts for Applications and Technologies.

Updated for COVID-19 Pandemic impact

With Executive and Consultant Guides

2021 to 2025



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the X-Ray market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- i. Genetic Testing - Strategic Situation Analysis & Impact of COVID-19 Pandemic21
 - a**23
- ii. Guide for Executives, Marketing, Sales and Business Development Staff23
- iii. Guide for Management Consultants and Investment Advisors25
- 1. Introduction and Market Definition27
 - 1.1 Genetic Testing Definition in This Report 28
 - 1.2 The Genomics Revolution 29
 - 1.3 Market Definition 31
 - 1.3.1 Revenue Market Size..... 31
 - 1.3.1 Newborn Screening 32
 - 1.3.2 Non Invasise Pregnancy Testing 32
 - 1.3.3 Predictive 32
 - 1.3.4 Oncology 32
 - 1.3.5 Direct to Consumer 32
 - 1.3.6 Other Application..... 32
 - 1.3.7 PCR 33
 - 1.3.4 NGS..... 33
 - 1.3.5 Cytogenetic..... 33
 - 1.3.6 Other Technology 33
 - 1.4 U.S. Medical Market and laboratory Testing - Perspective 34
 - 1.4.1 U.S. Medicare Expenditures for Laboratory Testing 35

2. Market Overview37

2.1 Market Participants Play Different Roles 38

 2.1.1 Supplier/pharmaceutical 39

 2.1.2 Independent lab specialized/esoteric 39

 2.1.3 Independent lab national/regional..... 39

 2.1.4 Independent lab analytical 40

 2.1.5 Public National/regional lab 40

 2.1.6 Hospital lab 40

 2.1.7 Physician lab 41

 2.1.8 DTC Lab..... 41

 2.1.9 Independent Genetic Testing Lab..... 41

 2.1.10 Audit Body..... 42

2.2 Genetic Tests –Types, Examples and Discussion 43

 2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market 43

 2.2.2 Prenatal Diagnosis – New Technologies Create Opportunity 44

 2.2.3 Newborn Screening 44

 2.2.2 Diagnostic Testing 45

 2.2.3 Carrier Testing 45

 2.2.6 Predictive and Presymptomatic Testing 46

 2.2.7 Pharmacogenomics 46

 2.2.8 Forensic Testing..... 47

 2.2.9 Parental Testing 47

 2.2.10 Ancestral Testing..... 47

2.3 Industry Structure 49

- 2.3.1 Hospital's Testing Share 49
- 2.3.2 Economies of Scale 49
 - 2.3.2.1 Hospital vs. Central Lab 50
- 2.3.3 Physician Office Lab's 51
- 2.3.4 Physician's and POCT 51
- 2.4 Market Shares of Key Genetics Players - Analysis 52
- 3. Market Trends.....53
 - 3.1 Factors Driving Growth..... 54
 - 3.1.1 Genetic Discoveries Creating New Diagnostic Markets 54
 - 3.1.2 Aging Population a Boon for Diagnostics..... 55
 - 3.1.3 Pharmacogenomics Drives Further Growth. 56
 - 3.1.4 Oncology and Liquid Biopsy Enter New Era..... 56
 - 3.1.5 Fertility Practice Growth drives market 57
 - 3.1.6 Direct to Consumer begins to break out..... 57
 - 3.2 Factors Limiting Growth..... 58
 - 3.2.1 Increased Competition Lowers Price 58
 - 3.2.2 Lower Costs..... 59
 - 3.2.3 Testing usage analysis curtailing growth. 59
 - 3.2.4 Wellness has a downside 59
 - 3.3 Instrumentation and Automation..... 61
 - 3.3.1 Instruments Key to Market Share 61
 - 3.3.2 Bioinformatics Plays a Role. 61
 - 3.4 Diagnostic Technology Development 62
 - 3.4.1 Next Generation Sequencing Fuels a Revolution..... 63

- 3.4.2 Impact of NGS on pricing 64
- 3.4.3 POCT/Self Testing Disruptive Force 64
- 3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment 65
- 3.4.5 CGES Testing, A Brave New World 66
- 3.4.6 Biochips/Giant magneto resistance based assay 66
- 4. Genetic Testing Recent Developments68
 - 4.1.1 Importance of This Section 68
 - 4.1.2 How to Use This Section..... 68
- Agios Pharmaceuticals, PerkinElmer Partner on Hereditary Anemia Genetic Testing 68
- Tumor, Germline Testing of Cancer Patients Can Give Discordant Results 69
- Invitae Completes Acquisition of ArcherDx 71
- Prenetics Receives \$15M Investment..... 72
- Sanford Health Invests \$800K in TruGenomix as Part of PTSD Test Alliance 73
- Preconception Carrier Screening Trial Begins in Australia..... 73
- Genetic Testing Clinical Use Just Beginning 74
- Fulgent Genetics Q1 Revenues Jump 44 Percent 76
- Blueprint Genetics, NICER Consortium Developing Genetic Test for Immunologic, Hematologic Disorders..... 77
- Natera Terminates Qiagen Agreement for Developing NGS-Based Genetic Tests 78
- Invitae Acquires Three Companies: YouScript, Genelex, Diploid..... 79
- Thermo Fisher Scientific to Buy Qiagen for \$11.5B 81
- PerkinElmer SCID Test Chosen for Newborn Screening Evaluation in England 83
- Germline Cancer Risk Mutations Sometimes Reported in Tumor Testing 84
- Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America 91

Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients 92

Phosphorus Offers DNA Testing to Assess Disease Risk..... 94

Arivale Shuts Down Personalized Wellness Business 95

ArcherDX Acquires Baby Genes 96

MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay 97

Thermo Fisher Purchases 9 Percent Stake in Yourgene Health..... 98

Invitae Partners to Expand Free Epilepsy Genetic Testing Program..... 99

Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx 100

NanoString Technologies Prices \$103.5M Common Stock Offering 101

Canine Consumer Genomics Firm Embark Veterinary Raises \$10M 102

Yourgene Health to Acquire Elucigene..... 102

Helix, AdventHealth Partner on Genetic Screening Study..... 103

Qiagen, NeuMoDx Ink Partnership, Merger Agreement 104

5. Profiles of Key Companies 106

 10x Genomics, Inc..... 107

 23andME Inc..... 108

 Abbott Diagnostics 110

 AccuraGen Inc. 112

 Adaptive Biotechnologies..... 113

 Admera Health, LLC..... 114

 Agena Bioscience, Inc..... 115

 Agilent 117

 Akonni Biosystems 119

 Ancestry.com LLC 120

Anchor Dx	122
ArcherDx, Inc.	123
ARUP Laboratories.....	124
Asuragen.....	126
Baylor Miraca Genetics Laboratories	128
Beckman Coulter, Inc.	129
Becton, Dickinson and Company	131
BGI Genomics Co. Ltd	133
Bioarray Genetics.....	135
Biocept, Inc.....	136
Biodesix Inc.	137
BioFluidica	138
BioGenex	139
Biolidics Ltd.....	141
bioMérieux Diagnostics.....	142
Bioneer Corporation	144
Bio-Rad Laboratories, Inc.	146
Bio-Techne	148
Cancer Genetics.....	150
Caris Molecular Diagnostics	152
CellMax Life	153
Centogene	154
Chronix Biomedical.....	158
Circulogene.....	159

Clinical Genomics 160

Color Genomics 161

Complete Genomics, Inc. – A BGI Company 162

Cynvenio..... 164

Dante Labs 165

Datar Cancer Genetics Limited..... 167

Diasorin S.p.A. 168

Epic Sciences..... 169

Epigenomics AG 170

Eurofins Scientific 171

Excellerate Bioscience 174

Exosome Diagnostics 175

Fabric Genomics..... 177

Fluidigm Corp 178

Foundation Medicine 180

Freenome..... 181

FUJIFILM Wako Diagnostics..... 182

Fujirebio 183

GE Global Research 184

GE Healthcare Life Sciences 186

Gene by Gene, Ltd..... 188

Genedrive..... 190

GeneFirst Ltd..... 191

Genetron Health (Beijing) Co., Ltd. 192

Genewiz 193

Genomic Health..... 194

Genomics England 196

Genomics Personalized Health (GPH) 198

GenomOncology..... 200

Genzyme Corporation..... 201

Grail, Inc..... 203

Grifols..... 205

Guardant Health 206

Guardiome 207

HeiScreen..... 209

Helix 210

Helomics..... 212

Hologic 213

Horizon Discovery 215

HTG Molecular Diagnostics 217

Human Longevity, Inc..... 219

iCellate 221

Illumina 222

Incell Dx..... 223

Inivata 224

Integrated Diagnostics 225

Invitae Corporation..... 226

Invivoscribe 228

Karius 229

Macrogen..... 230

MDNA Life SCIENCES, Inc..... 231

MDx Health 232

Medgenome 233

Meridian Bioscience..... 234

Mesa Biotech..... 236

MIODx..... 237

miR Scientific..... 238

MNG Labs 239

Molecular MD 240

NantHealth, Inc. 241

Natera 243

Nebula Genomics 245

NeoGenomics 246

New Oncology 248

Novogene Bioinformatics Technology Co., Ltd..... 249

Omega Bioservices 251

OncoDNA 253

ORIG3N, Inc. 254

Origene Technologies..... 256

Oxford Nanopore Technologies 257

Pacific Biosciences..... 260

Panagene 261

Perkin Elmer..... 262

Personal Genome Diagnostics..... 264

Personalis 265

Precipio 266

PrecisionMed 267

Promega 268

Protagen Diagnostics..... 270

Qiagen Gmbh 271

Quantumdx 274

Regeneron..... 275

Roche Molecular Diagnostics 277

Roswell Biotechnologies 279

Seegene 280

Sequencing.com..... 282

Siemens Healthineers 284

simfo GmbH 286

Singlera Genomics Inc..... 287

SkylineDx 288

Stratos Genomics 289

Sure Genomics, Inc. 290

Sysmex..... 292

Sysmex Inostics 293

Tempus Labs, Inc. 295

Thermo Fisher Scientific Inc..... 296

Veritas Genetics 298

Volition 300

6. Global Market Size.....301

6.1 Global Market by Country 302

6.1.1 Table – Global Market by Country..... 302

6.1.2 Chart – Country Market Shares 303

6.2 Global Market by Application..... 304

6.2.1 Table – Global Market by Application 304

6.2.2 Chart – Application Share by Year 305

6.2.3 Chart – Application Segment Growth Rates 306

6.2.4 Chart – Application Segment Share Shifts..... 307

6.2.5 Chart – Application Segment Share Base Year 308

6.2.6 Chart – Application Segment Share Final Year 309

6.3 Global Market by Technology..... 310

6.3.1 Table – Global Market by Technology 310

6.3.2 Chart – Technology Share by Year 311

6.3.3 Chart – Technology Segment Growth Rates 312

6.3.4 Chart – Technology Segment Share Shifts..... 313

6.3.5 Chart – Technology Segment Share Base Year 314

6.3.6 Chart – Technology Segment Share Final Year 315

7. Market Sizes by Application316

7.1 Newborn Testing Market 317

7.1.1 Table Newborn – by Country..... 317

7.1.2 Chart – Newborn Growth 318

- 7.2 NIPT Market 319
 - 7.2.1 Table NIPT – by Country 319
 - 7.2.2 Chart – NIPT Growth 320
- 7.3 Predictive Testing Market 321
 - 7.3.1 Table Predictive – by Country 321
 - 7.3.2 Chart – Predictive Growth 322
- 7.4 Oncology Testing Market 323
 - 7.4.1 Table Oncology – by Country 323
 - 7.4.2 Chart – Oncology Growth 324
- 7.5 DTC Testing Market 325
 - 7.5.1 Table DTC – by Country 325
 - 7.5.2 Chart – DTC Growth 326
- 7.6 Other Testing Market 327
 - 7.6.1 Table Other – by Country 327
 - 7.6.2 Chart – Other Growth 328
- 8. Global Genetic Testing Market by Technology 329
 - 8.1 PCR Testing Market 330
 - 8.1.1 Table PCR – by Country 330
 - 8.1.2 Chart – PCR Growth 331
 - 8.2 NGS Market 332
 - 8.2.1 Table NGS – by Country 332
 - 8.2.2 Chart – NGS Growth 333
 - 8.3 Cytogenetic Testing Market 334
 - 8.3.1 Table Cytogenetic – by Country 334

- 8.3.2 Cytogenetic – Predictive Growth 335
- 8.4 Other Testing Market 336
 - 8.4.1 Table Other – by Country 336
 - 8.4.2 Chart – Other Growth 337
- 9. The Future of Genetic Testing338
- Appendices339
 - I. United States Medicare System: January 2020 laboratory Fees Schedule 339
 - II Methodology 431
 - II.1 Authors..... 431
 - II.2 Sources 431

Table of Tables

Table 1 Most Common Traditional Genetic Disorders	29
Table 2 Lab Spending 2014 to 2024	36
Table 3 Market Players by Type	38
Table 4 The Different Types of Genetic Tests	43
Table 5 Five Factors Driving Growth	54
Table 6 Four Factors Limiting Growth	58
Table 7 Key Diagnostic Laboratory Technology Trends	62
Table 8 Next Generation Sequencing Technologies – Speed and Cost	63
Table 9 Global Market by Country	302
Table 10 Global Market by Application.....	304
Table 11 Global Market by Technology	310
Table 12 Newborn Segment by Country	317
Table 13 NIPT Segment by Country	319
Table 14 Predictive Segment by Country	321
Table 15 Oncology Segment by Country	323
Table 16 DTC Segment by Country	325
Table 17 Other Segment by Country	327
Table 18 PCR Segment by Country	330
Table 19 NGS Segment by Country.....	332
Table 20 Cytogenetic Segment by Country	334
Table 21 Other Segment by Country	336

Table 22 2020 CLINICAL LAB FEE SCHEDULE..... 339

Table of Figures

Figure 1 Clinical Lab Spending 2014 to 2024	35
Figure 2 Top Ten Sequencing Companies.....	52
Figure 3 Percentage of World Population Over 65.....	55
Figure 4 Country Market Shares.....	303
Figure 5 Application Share by Year.....	305
Figure 6 Application Segment Growth Rates	306
Figure 7 Segment Share Shifts	307
Figure 8 Application Segment Share Base Year	308
Figure 9 Application Segment Share Final Year	309
Figure 10 Technology Share by Year.....	311
Figure 11 Technology Segment Growth Rates	312
Figure 12 Technology Segment Share Shifts	313
Figure 13 Technology Segment Share Base Year	314
Figure 14 Technology Segment Share Final Year	315
Figure 15 Newborn vs. Total Market Growth	318
Figure 16 NIPT vs. Total Market Growth	320
Figure 17 Predictive vs. Total Market Growth	322
Figure 18 Oncology vs. Total Market Growth	324
Figure 19 DTC vs. Total Market Growth	326
Figure 20 Other vs. Total Market Growth	328
Figure 21 PCR vs. Total Market Growth	331

Figure 22 NGS vs. Total Market Growth..... 333
Figure 23 Cytogenetic vs. Total Market Growth..... 335
Figure 24 Other vs. Total Market Growth 337